Target Validation Information
TTD ID	T52297
Target Name	Oxysterols receptor LXR-alpha (NR1H3)
Type of Target	Patented-recorded
Drug Potency against Target		Drug Info	IC50 = 179 nM	[4]
	12,17-dehydroxyriccardin C	Drug Info	IC50 = 5700 nM	[2]
	12-dehydroxyriccardin C	Drug Info	IC50 = 4400 nM	[2]
	17-dehydroxyriccardin C	Drug Info	IC50 = 6600 nM	[2]
	2-(2-hexylphenyl)isoindoline-1,3-dione	Drug Info	IC50 = 13000 nM	[2]
	2-(2-phenethylphenyl)isoindoline-1,3-dione	Drug Info	IC50 = 9800 nM	[5]
	2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole	Drug Info	IC50 = 279 nM	[4]
	4,12,17-dehydroxyriccardin C	Drug Info	IC50 = 7100 nM	[2]
	4,17-dehydroxyriccardin C	Drug Info	IC50 = 3200 nM	[2]
	4-dehydroxyriccardin C	Drug Info	IC50 = 8400 nM	[2]
	GSK-9772	Drug Info	IC50 = 180 nM	[3]
	Guttiferone I	Drug Info	IC50 = 3400 nM	[1]
	GW-3965	Drug Info	IC50 = 100 nM	[4]
	Riccardin C	Drug Info	IC50 = 4900 nM	[2]
	WAY-214950	Drug Info	IC50 = 248 nM	[4]
References
REF 1	Guttiferone I, a new prenylated benzophenone from Garcinia humilis as a liver X receptor ligand. J Nat Prod. 2005 Apr;68(4):617-9.
REF 2	Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
REF 3	Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65.
REF 4	Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
REF 5	Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.